Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.60 |
| ▸ | RXRA | P19793 | 2/20 | 0.58 |
| ▸ | RXRB | P28702 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23581248 | 0.90 | NR1H4 (0.58) | KMORXRARXRBAKR1C3AKR1C2 | |
| SCHEMBL5423700 | 0.89 | KMO (0.56) | KMORXRARXRBAKR1C3AKR1C2 | |
| SCHEMBL28298835 | 0.87 | KMO (0.55) | KMORXRARXRBAKR1C3AKR1C2 | |
| SCHEMBL28717928 | 0.86 | DHODH (0.57) | KMORXRARXRBTYMSFFAR1 | |
| SCHEMBL10029693 | 0.86 | HSD17B1 (0.54) | KMOLMNAFFAR1NPC1SMN1; SMN2 | |
| SCHEMBL11227165 | 0.86 | KMO (0.72) | KMORXRARXRBKEAP1LMNA | |
| SCHEMBL12577690 | 0.85 | BRD4 (0.59) | FFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4262253 | 0.85 | PARP1 (0.60) | FFAR1TSHRDHODH | |
| SCHEMBL5428822 | 0.83 | RAB9A (0.51) | KMORXRARXRBAKR1C3AKR1C2 | |
| SCHEMBL15398033 | 0.83 | KMO (0.50) | KMORXRARXRBAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306131-B1 | Cross-coupling process using a catalyst comprising a cyclic nitrogen ligand | SUMITOMO CHEMICAL CO (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2011788-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20060111593-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-20030162950-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-28 | — | — | US | disclosed |
| EP-1306131-A2 | Cross-Coupling catalyst comprising a cyclic nitrogen ligand and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162950-A1 | Coupling catalyst and process using the same | NOD1, PYM1, C9 | KMO 401/4885RXRA 1603/4885RXRB 1579/4885 |
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | KMO 2211/4885RXRA 1327/4885RXRB 883/4885 |
| US-20060111593-A1 | Coupling catalyst and process using the same | RPL22, C9, RBM22 | KMO 663/4885RXRA 1333/4885RXRB 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.